Network and limited-distribution access
A clear read on which doors are open, which are closed, and what each one would take.
- Limited-distribution drug network access strategy
- Payer and PBM network participation review
- Manufacturer access criteria and data requirements
- Realistic sequencing of which networks to pursue first